Notice of Intent to Award a Sole Source Contract – Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak

The Food and Drug Administration (FDA) intends to award a Sole Source firm-fixed price purchase order to The University of Liverpool for the Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak. The primary objective of this requirement is to obtain critical reagents such as procure reference standards and internal standards to perform bioanalytical method development and sample analysis to determine the quantification of CYP enzyme substrates/metabolites and transporter substrates in hepatocyte experiments. • The procurement is being conducted under simplified acquisition procedures in accordance with FAR Part 12 (RFO). • The NAICS Code for this action is 541714 - Research and Development in Biotechnology (except Nanobiotechnology). • Responses to this notice should be sent to Ryan Alexander at [email protected] by 5:00 pm July 29, 2026.